Dr. Timothy Sebastian Pardee, MD, PhD

Dr. Pardee practices at Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina.

Dr. Pardee's NPI, 1740386010, was assigned on September 15, 2006. Dr. Pardee graduated from State University of New York at Buffalo School of Medicine in 2003. Dr. Pardee holds North Carolina license 2009-00253.

Dr. Pardee's primary practice is Davie Surgery - Ophthalmology - HOPD, at 329 Nc Highway 801 N, Bermuda Run, NC 27006.

Dr. Pardee's primary practice is Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina. Dr. Pardee is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Wake Forest Baptist. Dmand AI also links Dr. Pardee to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pardee practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pardee's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Pardee's licenses on file in 2 states: North Carolina and New York.

CMS data shows 308 Medicare services from Dr. Pardee across 5 procedure codes in 2024, for 80 Medicare patients. Medicare paid $21,105 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 80 Medicare patients who saw Dr. Pardee in 2024. The largest group is 75 to 84, with 34 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 15% are also on Medicaid. Their average risk score is 3.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pardee's median patient age at 72, with 46% women.

In 2024, Dr. Pardee wrote 94 Medicare Part D claims for 27 patients. 67% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $108 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

Dr. Pardee accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 131 general payments to Dr. Pardee from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Celgene Corporation paid the most, $73,565. It also lists 5 research payments totaling $2,414 in 2019.

Dr. Pardee graduated from State University of New York at Buffalo School of Medicine in 2003.